Role of Brain Biomarkers S-100-Beta and Neuron-Specific Enolase for Detection and Follow-Up of Hepatic Encephalopathy in Cirrhosis Before, During and After Treatment with L-Ornithine-L-Aspartate

Overview

Journal GE Port J Gastroenterol

Specialty Gastroenterology

Date 2020 Nov 30

PMID 33251288

Citations 3

Authors

Hendrik Strebel

Bernhard Haller

Maximilian Sohn

Wolfgang Schepp

Felix Gundling

Affiliations

Soon will be listed here.

Abstract

Introduction: Hepatic encephalopathy (HE), in the context of liver cirrhosis, seems to result from low-grade cerebral edema of the astrocytes. Serum brain biomarkers S-100-beta und neuron-specific enolase (NSE) are often elevated in brain injury. We hypothesized that neuromarkers S-100-beta and NSE can be used in the diagnosis of HE, compared with standardized diagnostic tools.

Material And Methods: A prospective non-randomized intervention study was performed using L-ornithine-L-aspartate (LOLA) for HE treatment. Primary endpoint was the evaluation of neuromarkers S-100-beta and NSE for detection and diagnosis of follow-up of HE. As secondary endpoints, the efficacy of LOLA on the course of HE and the diagnostic role of Portosystemic-Encephalopathy-Syndrome score (PHES) and critical flicker frequency (CFF) were analyzed. For diagnosis of covert (CHE) and overt (OHE) HE, West-Haven criteria (WHC), PHES and CFF were assessed at study entry. LOLA was applied (20 g i.v.) for 6 days. At the end of the study, HE evaluation was repeated. S-100-beta, NSE and ammonia were assessed in each patient before, during and after therapy with LOLA.

Results: 30 patients were included. At study entry, CHE was diagnosed in 50% and OHE in 50% of all subjects. A total of 25 participants completed the study. After LOLA therapy, deterioration of HE occurred in <11%, while most patients showed improvement (e.g. improved CFF in 79%). No significant correlation with HE severity (as diagnosed by WHC, PHES and CFF) could be demonstrated for any biochemical parameter. In addition, there were no significant changes in brain biomarkers during the treatment period.

Discussion: While CFF as well as PHES showed good correlation with treatment response, S-100-beta and NSE did not significantly correlate with HE severity compared to proven diagnostic methods, and do not seem reliable biochemical markers for the follow-up under therapy.

Citing Articles

[Advancements in the diagnosis and treatment of pediatric acute liver failure].

Ming H, He Y, Xu H Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(2):194-200.

PMID: 38436319 PMC: 10921869. DOI: 10.7499/j.issn.1008-8830.2309015.

S100B Protein but Not 3-Nitrotyrosine Positively Correlates with Plasma Ammonia in Patients with Inherited Hyperammonemias: A New Promising Diagnostic Tool?.

Czarnecka A, Obara-Michlewska M, Wesol-Kucharska D, Greczan M, Kaczor M, Ksiazyk J J Clin Med. 2023; 12(6).

PMID: 36983411 PMC: 10056255. DOI: 10.3390/jcm12062411.

Liquid Diagnosis of Hepatic Encephalopathy: Are We There Already?.

Verdelho Machado M GE Port J Gastroenterol. 2020; 27(6):378-382.

PMID: 33251286 PMC: 7670371. DOI: 10.1159/000510059.

References

Mohammad R, Regal R, Alaniz C . Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother. 2012; 46(11):1559-63. DOI: 10.1345/aph.1R146. View

Kircheis G, Hilger N, Haussinger D . Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy. Gastroenterology. 2013; 146(4):961-9. DOI: 10.1053/j.gastro.2013.12.026. View

Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen K . Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60(2):715-35. DOI: 10.1002/hep.27210. View

Montgomery J, Bajaj J . Advances in the evaluation and management of minimal hepatic encephalopathy. Curr Gastroenterol Rep. 2010; 13(1):26-33. DOI: 10.1007/s11894-010-0150-z. View

Bajaj J, Wade J, Gibson D, Heuman D, Thacker L, Sterling R . The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011; 106(9):1646-53. PMC: 3989143. DOI: 10.1038/ajg.2011.157. View

Stelzl T, von Bose M, Hogl B, Fuchs H, Flugel K . A comparison of the prognostic value of neuron-specific enolase serum levels and somatosensory evoked potentials in 13 reanimated patients. Eur J Emerg Med. 1995; 2(1):24-7. DOI: 10.1097/00063110-199503000-00006. View

Bass N, Mullen K, Sanyal A, Poordad F, Neff G, Leevy C . Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010; 362(12):1071-81. DOI: 10.1056/NEJMoa0907893. View

Gundling F, Zelihic E, Seidl H, Haller B, Umgelter A, Schepp W . How to diagnose hepatic encephalopathy in the emergency department. Ann Hepatol. 2013; 12(1):108-14. View

Labenz C, Worns M, Schattenberg J, Huber Y, Galle P, Labenz J . Epidemiology of hepatic encephalopathy in german hospitals - the EpHE study. Z Gastroenterol. 2017; 55(8):741-747. DOI: 10.1055/s-0043-114671. View

10.

Donato R . S-100 proteins. Cell Calcium. 1986; 7(3):123-45. DOI: 10.1016/0143-4160(86)90017-5. View

11.

Saleh A, Kamel L, Ghali A, Ismail A, El Khayat H . Serum levels of astroglial S100-beta and neuron-specific enolase in hepatic encephalopathy patients. East Mediterr Health J. 2008; 13(5):1114-23. DOI: 10.26719/2007.13.5.1114. View

12.

Wang K, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall J . An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018; 18(2):165-180. PMC: 6359936. DOI: 10.1080/14737159.2018.1428089. View

13.

Groeneweg M, de Knegt R, Hamberger A, Ding M, Wang S, Schalm S . Neuronal and glial marker proteins in encephalopathy associated with acute liver failure and acute hyperammonemia in the rabbit. Metab Brain Dis. 1993; 8(2):95-106. DOI: 10.1007/BF00996892. View

14.

Schomerus H, Hamster W . Neuropsychological aspects of portal-systemic encephalopathy. Metab Brain Dis. 1999; 13(4):361-77. DOI: 10.1023/a:1020645110880. View

15.

Amodio P, Del Piccolo F, Petteno E, Mapelli D, Angeli P, Iemmolo R . Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001; 35(1):37-45. DOI: 10.1016/s0168-8278(01)00129-5. View

16.

Weissenborn K, Ruckert N, Hecker H, Manns M . The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy. J Hepatol. 1998; 28(4):646-53. DOI: 10.1016/s0168-8278(98)80289-4. View

17.

Romero-Gomez M, Boza F, Garcia-Valdecasas M, Garcia E, Aguilar-Reina J . Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001; 96(9):2718-23. DOI: 10.1111/j.1572-0241.2001.04130.x. View

18.

Bajaj J, Hafeezullah M, Zadvornova Y, Martin E, Schubert C, Gibson D . The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am J Gastroenterol. 2009; 104(4):898-905. DOI: 10.1038/ajg.2009.7. View

19.

Jepsen P, Ott P, Andersen P, Sorensen H, Vilstrup H . Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010; 51(5):1675-82. DOI: 10.1002/hep.23500. View

20.

Lewis M, Howdle P . The neurology of liver failure. QJM. 2003; 96(9):623-33. DOI: 10.1093/qjmed/hcg110. View